Research Article

Clinicopathological Characteristics of Nonfunctional Pancreatic Neuroendocrine Neoplasms and the Effect of Surgical Treatment on the Prognosis of Patients with Liver Metastases: A Study Based on the SEER Database

Abuduhaibaier Sadula, Gang Li, Dianrong Xiu, Chen Ye, Siqian Ren, Xin Guo, and Chunhui Yuan

Department of General Surgery, Peking University Third Hospital, Beijing 100191, China

Correspondence should be addressed to Xin Guo; 1084371625@qq.com and Chunhui Yuan; chunhuiyuan2018@163.com

Abuduhaibaier Sadula and Gang Li contributed equally to this work.

Received 17 February 2022; Revised 23 March 2022; Accepted 11 April 2022; Published 12 May 2022

Academic Editor: Min Tang

Copyright © 2022 Abuduhaibaier Sadula et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The incidence of nonfunctional pancreatic neuroendocrine neoplasms (NF-pNENs) has been increasing annually. This study is aimed at investigating the clinicopathological characteristics and high-risk factors of NF-pNENs and the influence of surgical treatment on the prognosis of NF-pNEN patients with liver metastases. Methods. pNEN patients in this study were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. This study analyzed patients diagnosed with NF-pNENs from 2000 to 2017 who met the inclusion criteria. A retrospective analysis of the clinicopathological characteristics of NF-pNEN patients was conducted. Kaplan-Meier method was used to calculate the survival time. A multivariate Cox regression model was used to analyze the survival outcomes and risk factors. Results. From 2000 to 2017, the SEER database registered 10576 patients with pNENs and 1774 patients with liver metastases. Cox analysis revealed that age, sex, primary site, grade, tumor stage, surgery, tumor size, and liver metastasis were risk factors of prognosis, with grade being the most influential index. Patients with NF-pNENs with liver metastasis and no metastasis had different primary site, grade, and tumor size. In general, a higher grade was associated with a larger tumor and a greater risk of liver metastasis. Meanwhile, patients with liver metastasis showed that those with tumors originated from the tail of the pancreas had better prognoses than those with tumors originated from other parts. Surgical treatment can improve the prognosis of patients with liver metastases, despite the tumor grade. Conclusions. The incidence of pNENs has been increasing annually, and the liver has been the most common site of metastasis. Liver metastasis in patients with NF-pNENs, related to tumor size and grade, affected their long-term survival. Surgery significantly improved the prognosis of patients with liver metastases secondary to NF-pNENs with different grades.

1. Introduction

Pancreatic neuroendocrine neoplasms (pNENs) are a variety of heterogeneous tumors originated from pancreatic neuroendocrine cells, accounting for 8.7% of gastrointestinal pancreatic neuroendocrine tumors and 1%–2% of all pancreatic tumors [1]. According to clinical manifestations, pNENs can be divided into functional pNENs and nonfunctional pNENs (NF-pNENs). Functional pNENs are characterized by tumor tissues that can secrete insulin, gastrin, glucagon, somatostatin, and vasoactive intestinal peptide, producing corresponding clinical symptoms. The most common types include gastrinomas and insulinomas. NF-pNENs usually manifest with nonspecific symptoms, such as abdominal
Inclusion and exclusion criteria

10594 pNENs patients were registered in the SEER database from 2000 to 2017

2944 patients with NF-pNENs were enrolled in this study

529 NF-pNENs patients with liver metastases.

212 NF-pNENs patients with liver metastases underwent surgery

317 NF-pNENs patients with liver metastases did not undergo surgery

Figure 1: Inclusion and exclusion flowchart.

Figure 2: (a) Epidemiological prevalence of pNENs from 2000 to 2017. (b) Distant metastasis of pNENs. (c) Impact of liver metastasis and no metastasis on the survival of pNEN patients.
pain, bloating, or weight loss. Most pNENs are NF-pNENs [2]. PNENs encompass tumors with a wide spectrum of clinical behaviors. Consequently, these tumors are often diagnosed at an advanced stage [3]. At the time of diagnosis, approximately 40%–93% of patients with NF-pNENs have metastases, such as the lung and bone metastases, with the liver being the most common site of metastasis [4]. Besides, the potential survival benefits of surgery need to outweigh the morbidity associated with pancreatic surgery which explains the current controversy regarding small asymptomatic NF-pNENs [5–7]. Some of which advocated surgical treatment while others recommend conservative treatment. Therefore, studying the clinicopathological characteristics and high-risk factors of patients with NF-pNENs are important for improving patient prognosis.

The Surveillance, Epidemiology, and End Results (SEER) database is a publicly available cancer reporting system funded by the federal government and represents a collaboration between the CENTERS for Disease Control and Prevention, the National Cancer Institute, and regional and state cancer registries [8]. Our motivation is to use SEER data to analyze the epidemiology and survival of patients with pancreatic neuroendocrine neoplasms; furthermore, we also aimed to confirm the potential prognostic factors that might provide more robust evidence for surgeons to make determinations for selecting operable patients.

2. Data and Methods

2.1. Data Source. This study used data from the Surveillance, Epidemiology, and End Results (SEER) database (https://seer.cancer.gov/data/) sponsored by the National Cancer Institute, including data on age at diagnosis, sex, race, pathological type, grade, tumor stage, primary site, surgery, tumor size, liver metastasis, survival time, and survival status.

2.2. Inclusion and Exclusion Criteria. This study used the data from the SEER database updated in September 2020 and selected data from 2000 to 2017 to analyze the prevalence of pNENs, focusing on the clinicopathological characteristics, presence of liver metastasis, and the effect of surgical treatment on prognosis. The screening process is shown in Figure 1. The specific inclusion criteria were as follows: (1) patients diagnosed before 2015 to ensure a follow-up time more than 5 years; (2) the International Classification of Disease for Oncology (3rd Edition) was limited to the following pathological types: pancreatic endocrine tumors (8150), carcinoid tumors (8240), enterochromocytoid tumors (8242), cup shape cell carcinoids (8243), mixed glandular neuroendocrine tumors (8244), adenocarcinoids (8245), neuroendocrine carcinomas (8246), and atypical carcinoids (8249); (3) the location of ICD-O-3 was limited to the pancreas; and (4) tumors confirmed by histology. The exclusion criteria were as follows: (1) patients with unclear surgical history and (2) patients with metastases in other parts rather than liver metastasis.

### Table 1: Clinicopathological characteristics and univariate analysis of patients with NF-pNENs registered in the SEER database (2000-2017).

| Characteristics | Number of patients (n = 2944) (%) | Survival rate (%) 3 years | Survival rate (%) 5 years | P value |
|-----------------|---------------------------------|--------------------------|--------------------------|--------|
| Age (years)     |                                 |                          |                          |        |
| ≤60             | 1421 (63.7)                     | 86.9                     | 81.4                     | <0.001 |
| >60             | 1523 (36.3)                     | 74.6                     | 67.2                     |        |
| Sex             |                                 |                          |                          | <0.001 |
| Male            | 1626 (55.2)                     | 77.6                     | 70.7                     |        |
| Female          | 1318 (44.8)                     | 84.2                     | 78.3                     |        |
| Race            |                                 |                          |                          | 0.052  |
| White           | 2324 (78.9)                     | 79.7                     | 73.2                     | <0.001 |
| Black           | 328 (11.1)                      | 81.2                     | 77.1                     |        |
| Others          | 292 (9.9)                       | 85.7                     | 78.2                     |        |
| Primary site    |                                 |                          |                          | <0.001 |
| Head            | 863 (29.3)                      | 75.0                     | 69.3                     |        |
| Body            | 454 (15.4)                      | 85.9                     | 80.2                     |        |
| Tail            | 1116 (37.9)                     | 84.0                     | 78.1                     |        |
| Islet           | 17 (0.6)                        | 85.2                     | 80.6                     |        |
| Others          | 92 (3.1)                        | 82.8                     | 74.4                     |        |
| Overlapping     | 192 (6.5)                       | 75.3                     | 65.2                     |        |
| NOS             | 210 (7.1)                       |                          |                          |        |
| Grade           |                                 |                          |                          | <0.001 |
| G1              | 2104 (71.5)                     | 86.4                     | 80.5                     |        |
| G2              | 570 (19.4)                      | 81.4                     | 72.9                     |        |
| G3              | 200 (6.8)                       | 34.1                     | 28.2                     |        |
| G4              | 70 (2.4)                        | 24.2                     | 20.8                     |        |
| Tumor stage     |                                 |                          |                          | <0.001 |
| Localized       | 1572 (53.4)                     | 91.1                     | 86.3                     |        |
| Regional        | 730 (24.8)                      | 83.7                     | 77.8                     |        |
| Distant         | 642 (21.8)                      | 51.4                     | 40.9                     |        |
| Surgery         |                                 |                          |                          | <0.001 |
| Yes             | 2297 (78.0)                     | 73.7                     | 34.7                     |        |
| No              | 647 (22.0)                      | 73.9                     | 32.1                     |        |
| Tumor size (mm) |                                 |                          |                          | <0.001 |
| 1-20            | 1136 (38.6)                     | 88.0                     | 83.9                     |        |
| 21-40           | 930 (31.6)                      | 80.7                     | 72.1                     |        |
| ≥40             | 878 (29.8)                      | 70.7                     | 63.9                     |        |
| Metastasis      |                                 |                          |                          | <0.001 |
| Liver metastasis| 529 (18.0)                      | 52.3                     | 41.1                     |        |
| No metastasis   | 2415 (82.0)                     | 86.8                     | 81.5                     |        |

NOS: not otherwise specified. Univariate analysis was calculated by the Kaplan-Meier method with the log-rank test; P < 0.05 was considered statistically significant.

2.3. Statistical Analysis. The categorical data were presented as n (%) Univariate analysis was performed to analyze the demographic and tumor characteristics, while the Kaplan-
Meier survival curve method was performed to analyze patient survival. Multivariate analysis included statistically significant univariate analysis results. A Cox proportional hazard model was then established, and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to assess the strength of a single variable. All statistical analyses were performed using SPSS version 22.0 (IBM, New York, USA), and all figures were made using GraphPad Prism7.0 (GraphPad, CA, USA). Statistical significance was set at $P < 0.05$.

3. Results

3.1. Prevalence of pNENs and Clinicopathological Characteristics of NF-pNENs. From 2000 to 2017, 10594 patients with pNENs were registered in the SEER database. The prevalence of pNENs has increased significantly, leading to a concomitant rise in the number of registered NF-pNEN cases (Figure 2(a)). Among them, 2163 (20.4%) patients had distant metastases, and 1774 (16.7%) had liver metastases (Figure 2(b)), which was associated with a poor prognosis (Figure 2(c)). This study included 2944 patients with NF-pNENs, accounting for 27.8% (2944/10574) of the total number of registered patients with pNENs. Table 1 shows the clinicopathological characteristics of patients with NF-pNENs. The median age was 61 years (range, 11–85 years), and the average age at onset was 59.9 ± 13.3 years. There were more men than women (male : female = 1 : 23), and 78.9% were white. The top three tumor sites were the pancreatic tail (37.9%), head (29.3%), and body (15.4%).

### Table 2: Predictors of survival identified by multivariate Cox regression analysis.

| Variable               | Hazard ratio | 95% CI       | $P$ value |
|------------------------|--------------|--------------|-----------|
| Age (years)            |              |              |           |
| ≤60                    | 1.000        |              |           |
| >60                    | 1.997        | 1.707-2.336  | <0.001    |
| Sex                    |              |              |           |
| Male                   | 1.000        |              |           |
| Female                 | 0.700        | 0.600-0.817  | <0.001    |
| Primary site           |              |              |           |
| Head                   | 1.000        |              |           |
| Body                   | 0.545        | 0.424-0.701  | <0.001    |
| Tail                   | 0.634        | 0.529-0.759  | <0.001    |
| Islet                  | 0.792        | 0.327-1.921  | 0.606     |
| Others                 | 0.556        | 0.335-0.922  | 0.023     |
| Overlapping            | 1.020        | 0.769-1.352  | 0.892     |
| NOS                    | 0.978        | 0.739-1.293  | 0.874     |
| Grade                  |              |              |           |
| G1                     | 1.000        |              |           |
| G2                     | 1.399        | 1.147-1.707  | 0.001     |
| G3                     | 6.736        | 5.542-8.187  | <0.001    |
| G4                     | 9.225        | 6.883-12.365 | <0.001    |
| Tumor stage            |              |              |           |
| Localized              | 1.000        |              |           |
| Regional               | 1.753        | 1.414-2.173  | <0.001    |
| Distant                | 6.222        | 5.210-7.431  | <0.001    |
| Surgery                |              |              |           |
| Yes                    | 1.000        |              |           |
| No                     | 5.853        | 5.035-6.805  | <0.001    |
| Tumor size (mm)        |              |              |           |
| 1-20                   | 1.000        |              |           |
| 21-40                  | 1.761        | 1.440-2.152  | <0.001    |
| ≥40                    | 2.573        | 2.128-3.112  | <0.001    |
| Metastasis             |              |              |           |
| Liver metastasis       | 1.000        |              |           |
| No metastasis          | 0.232        | 0.200-0.270  | <0.001    |

NOS: not otherwise specified. $P < 0.05$ was considered statistically significant.

### Table 3: Demographic and clinical characteristics of NF-pNEN patients with liver metastasis versus no metastasis from 2000 to 2017 in the SEER database.

| Characteristics | Liver metastasis | No metastasis | $\chi^2$ value | $P$ value |
|----------------|------------------|---------------|----------------|-----------|
| Age (years)    |                  |               |                |           |
| ≤60            | 266 (50.3)       | 1155 (47.8)   | 1.050          | 0.306     |
| >60            | 263 (49.7)       | 1260 (52.2)   |                |           |
| Sex            |                  |               |                |           |
| Male           | 311 (58.8)       | 1315 (54.5)   | 3.304          | 0.069     |
| Female         | 218 (41.2)       | 1100 (45.5)   |                |           |
| Race           |                  |               |                |           |
| White          | 425 (80.3)       | 1899 (78.6)   | 0.933          | 0.627     |
| Black          | 57 (10.8)        | 271 (11.2)    |                |           |
| Others         | 47 (8.9)         | 245 (10.1)    |                |           |
| Primary site   |                  |               |                |           |
| Head           | 161 (30.4)       | 702 (29.1)    | 35.397         | <0.001    |
| Body           | 46 (8.7)         | 408 (16.9)    |                |           |
| Tail           | 211 (39.9)       | 905 (37.5)    |                |           |
| Islet          | 3 (0.6)          | 14 (0.6)      |                |           |
| Others         | 12 (2.3)         | 80 (3.3)      |                |           |
| Overlapping    | 54 (10.2)        | 138 (5.7)     |                |           |
| NOS            | 42 (7.9)         | 168 (7.0)     |                |           |
| Grade          |                  |               |                |           |
| G1             | 245 (46.3)       | 1859 (77.0)   | 255.107        | <0.001    |
| G2             | 140 (26.5)       | 430 (17.8)    |                |           |
| G3             | 94 (17.8)        | 106 (4.4)     |                |           |
| G4             | 38 (7.2)         | 32 (1.3)      |                |           |
| Tumor size (mm)|                  |               |                |           |
| 0-20           | 42 (7.9)         | 1094 (45.3)   | 60.744         | <0.001    |
| 21-40          | 177 (33.5)       | 753 (31.2)    |                |           |
| ≥40            | 310 (58.6)       | 568 (23.5)    |                |           |

NOS: not otherwise specified. $P < 0.05$ was considered statistically significant.
Furthermore, most patients had low-grade tumors, with 71.5% patients having G1 grade. The median tumor size was 35 mm, and the average tumor size was 27 ± 28 mm (range, 1–300 mm). Most patients had local tumors (53.4%), while 529 (18%) patients had liver metastasis.

3.2. Prognostic Factors Affecting the Survival of Patients with NF-pNENs. The median survival time of NF-pNEN patients was 42 months (average, 43 ± 4 months, range 0–95 months). Univariate analysis revealed that age, sex, primary site, grade, tumor stage, surgery, tumor size, and liver metastasis were related to long-term survival. In addition, we performed multivariate Cox regression analysis based on the results of the univariate analysis, which showed that age, sex, primary site, grade, tumor stage, surgical treatment, tumor size, and liver metastasis were independent factors that affected prognosis. Grade was the most significant indicator (HR: 9.225, CI: 6.883–12.365, Table 2).

3.3. Clinical Characteristics of NF-pNEN Patients with Liver Metastasis. Survival analysis showed that the occurrence of liver metastasis indicated a poor prognosis (Figure 2(c)). The clinical characteristics of major liver metastasis and no metastasis NF-pNENs were compared to clarify the pathological characteristics of patients with liver metastasis secondary to NF-pNENs. Of the 2944 patients, 529 patients had liver metastasis. The demographic, clinical, and pathological characteristics are summarized in Table 3. Patients with NF-pNENs with metastasis and no metastasis had different primary site, grade, and tumor size. In general, the higher the grade and the larger the tumor, the higher the proportion of liver metastasis (P < 0.001, Figure 3).

3.4. Factors Affecting the Survival of NF-pNEN Patients with Liver Metastasis. Table 3 shows that primary site, grade, tumor size, and surgical treatment affected the prognosis of NF-pNEN patients with liver metastasis. Cox regression analysis of the above factors revealed that tumors originated from the tail of the pancreas had better prognoses than those originated from other sites (HR: 0.676, CI: 0.514–0.888). A higher grade (HR: 3.448, CI: 2.274–5.229) and not receiving surgical treatment (HR: 3.645, CI: 2.773–4.79) also affected the prognosis (Table 4).

3.5. Impact of Surgery on the Survival of Patients with Liver Metastasis from Different Grades of NF-pNENs. Liver metastasis secondary to NF-pNENs affected the long-term survival of the 529 patients diagnosed with metastasis; of them, 212 (40.1%) patients received surgical treatment. Survival analysis showed that the survival of the surgical treatment group improved compared with the nonsurgery group. Since the prognosis of metastatic NF-pNENs varied depending on the grade, we merged the two highly differentiated tumors, G1 and G2 grades, and the two poorly differentiated and undifferentiated tumors, G3 and G4, to analyze survival. The analysis showed that the prognosis of patients with moderately and highly differentiated tumors was significantly better than those with poorly differentiated and undifferentiated tumors. In tumors of different grades, surgical treatment can improve the prognosis of patients with liver metastases (Figure 4).

4. Discussion

The number of NF-pNEN cases registered in the SEER database increased significantly from 2000 to 2017. Because NF-pNENs lack typical symptoms in the early stage and the patient’s survival time is affected by liver metastasis, it is necessary to identify related risk factors and formulate the best treatment strategy [9].
Table 4: Predictors of survival identified by multivariate Cox regression analysis in NF-pNEN patients with liver metastasis.

| Variable          | Number of NF-pNEN patients with liver metastasis (N = 529) (%) | Survival rate (%) | P value | Hazard ratio | 95% CI | P value |
|-------------------|---------------------------------------------------------------|-------------------|---------|--------------|--------|---------|
|                   |                                                               | 3 years           | 5 years |              |        |         |         |
| Primary site      |                                                               |                   |         |              |        |         |         |
| Head              | 161 (30.3)                                                    | 47.7              | 33.8    | 1.000        |        |         |         |
| Body              | 46 (8.7)                                                     | 50.6              | 44.3    | 0.691        | 0.442-1.080 | 0.104  |
| Tail              | 211 (40.0)                                                   | 57.1              | 46.7    | 0.676        | 0.514-0.888 | 0.005  |
| Islet             | 3 (0.5)                                                      | 0                 | 0       | 1.235        | 0.304-5.014 | 0.767  |
| Others            | 12 (2.3)                                                     | 50.0              | 50.0    | 0.670        | 0.294-1.527 | 0.341  |
| Overlapping       | 54 (10.2)                                                    | 51.5              | 37.4    | 0.787        | 0.523-1.183 | 0.249  |
| NOS               | 42 (8.0)                                                     | 49.1              | 29.7    | 0.946        | 0.606-1.478 | 0.809  |
| Grade             |                                                               |                   |         | <0.001       |        |         |         |
| G1                | 245 (46.3)                                                   | 63.4              | 48.4    | 1.000        |        |         |         |
| G2                | 140 (26.5)                                                   | 63.7              | 51.8    | 0.949        | 0.696-1.294 | 0.740  |
| G3                | 106 (20.0)                                                   | 21.8              | 16.8    | 3.410        | 2.574-4.516 | <0.001 |
| G4                | 38 (7.2)                                                     | 23.1              | 23.1    | 3.448        | 2.274-5.229 | <0.001 |
| Tumor size (mm)   |                                                               |                   |         | 0.333        |        |         |         |
| 0-20              | 42 (7.9)                                                      | 59.1              | 59.1    | 1.000        |        |         |         |
| 21-40             | 177 (33.5)                                                   | 53.8              | 40.0    | 1.390        | 0.850-2.275 | 0.190  |
| ≥40               | 310 (58.6)                                                   | 50.5              | 38.8    | 1.424        | 0.886-2.288 | 0.144  |
| Surgery           |                                                               |                   |         | <0.001       |        |         |         |
| Yes               | 212 (40.0)                                                   | 77.3              | 66.2    | 1.000        |        |         |         |
| No                | 317 (60.0)                                                   | 35.4              | 23.1    | 3.645        | 2.773-4.79 | <0.001 |

NOS: not otherwise specified. P < 0.05 was considered statistically significant.

Study has shown that in gastrointestinal-pancreatic neuroendocrine tumors, tumor size, high grade, and distant metastasis are associated with poor survival [10]. In 2017, the World Health Organization redefined the grade of neuroendocrine tumors. One of the main changes in the latest classification standard was the division of pNENs into well-differentiated tumors (NENs) and poorly differentiated tumors (NEC). Clinically, pNENs grow slowly and have a high survival rate, while pNECs grow rapidly and usually manifest as liver metastasis, active mitosis, and aggressive invasiveness [11, 12]. A higher grade is an independent prognostic indicator of shorter overall survival. When the grade increases, the survival time is greatly reduced. Gao et al. [13] found that G stage, TMN stage, lymph node, metastasis, vascular invasion, and the necrosis could be prognostic factors for pNENs. Therefore, patients with higher grades should be closely followed up. Therefore, determining the grades of primary tumors and metastatic tumors is vital for determining the prognosis and deciding on further treatment [14, 15].

Tumor size affects the possibility of metastasis [16]. According to the European Neuroendocrine Oncology Society standards, 2 and 4 cm were considered to be important thresholds affecting the prognosis in pNEN patient [17]. Some studies have indicated that tumor size is an independent prognostic factor associated with disease-free survival (DFS). If the tumor size is >30 mm after pancreatectomy, the risk of recurrence is higher [18]. Some studies have shown that NF-pNEN tumors measuring >20 mm are less malignant than tumors measuring <20 mm. For patients with sporadic, small NF-pNENs, developing a reasonable treatment strategy has always been controversial [19].

Surgery can significantly improve the symptoms and quality of life of patients with liver metastasis [20]. Zheng et al. [21] revealed that resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases. It should be adjusted according to tumor characteristics. Observation is usually recommended for asymptomatic patients with small pNENs, but for patients with F-pNENs and NF-pNENs measuring >20 mm, surgical resection should be performed [22]. In the era of transplantation oncology, liver transplantation has become a viable treatment option for patients with unresectable pNENs and liver metastases, improving the 5-year overall survival rate after liver transplantation to 47%–71%. For patients with unresectable or incurable tumors, liver transplantation should be the final choice after detailed discussion by a multidisciplinary team composed of all experts in the field. However, the high recurrence rate after liver transplantation is a clinical obstacle [23, 24].

This study has some limitations. First, it was a retrospective study. Second, as a database based on a large sample of people, the SEER database may lack some important clinical information, especially laboratory test results and detailed surgical records. Third, the tumor grading system was based on the old standard, which does not correspond well to the new standard.
With the advancement of diagnostic technology, more and more early asymptomatic NF-pNENs will be detected. After a multidisciplinary comprehensive evaluation, surgical treatment and targeted therapy can improve the long-term survival rate. However, the prognosis of patients with pNENs is not the same, the malignancy of tumors of different grades varies greatly, and there are still controversies about the treatment of pNENs of different sizes. Therefore, identifying the malignant degree of pNENs and exploring the clinicopathological characteristics of different types of tumors are of great significance for guiding treatment. It is hoped that the study of large populations in the SEER database can provide a basis for the treatment of pNENs.

5. Conclusions

The incidence of pNENs has been increasing year by year, and the liver is the most common site of metastasis. Patients with NF-pNENs were mostly men who were younger than 60 years, mostly at G1. The predominant site was the tail of the pancreas, and the tumors were mostly localized tumors measuring <20 mm. Liver metastasis associated with the tumor size and grade, which decreased the long-term survival of patients. Surgery significantly improved the prognosis of patients with liver metastases of NF-pNENs with different grades. Surgical treatment can significantly improve the 5-year survival rate in patients with liver metastases. Therefore, surgical treatment should be performed when surgical indications are met.

Data Availability

The labeled dataset used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no competing interests.
Authors’ Contributions
Abuduhaibaier Sadula and Gang Li contributed equally to this work.

Acknowledgments
This study was supported by the National Natural Science Foundation of China (81672862).

References
[1] B. Lawrence, B. I. Gustafsson, A. Chan, B. Svejda, M. Kidd, and I. M. Modlin, "The epidemiology of gastroenteropancreatic neuroendocrine tumors," Endocrinology and Metabolism Clinics, vol. 40, no. 1, pp. 1–18, 2011.
[2] T. R. Halldanarson, J. Rubin, M. B. Farnell, C. S. Grant, and G. M. Petersen, "Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors," Endocrine-Related Cancer, vol. 15, no. 2, pp. 409–427, 2008.
[3] J. Arakelyan, D. Zohrabyan, and P. A. Philip, "Molecular profile of pancreatic neuroendocrine neoplasms (panNENs): opportunities for personalized therapies," Cancer, vol. 127, no. 3, pp. 345–353, 2021.
[4] V. Mazzaferrro, A. Pulvirenti, and J. Coppa, "Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation?", Journal of Hepatology, vol. 47, no. 4, pp. 460–466, 2007.
[5] S. M. Sharpe, H. In, D. J. Winchester, M. S. Talamonti, and M. S. Baker, "Surgical resection provides an overall survival benefit for patients with small pancreatic neuroendocrine tumors," Journal of Gastrointestinal Surgery, vol. 19, no. 1, pp. 117–123, 2015.
[6] S. Partelli, R. Cirocchi, S. Crippa et al., "Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms," Journal of British Surgery, vol. 104, no. 1, pp. 34–41, 2016.
[7] V. Sallinen, C. Haglund, and H. Seppänen, "Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: do size and symptoms matter?", Surgery, vol. 158, no. 6, pp. 1556–1563, 2015.
[8] C. Zeng, W. Wen, A. K. Morgans, W. Pao, X.-O. Shu, and W. Zheng, "Disparities by race, age, and sex in the improvement of survival for major cancers," JAMA Oncology, vol. 1, no. 1, pp. 88–96, 2015.
[9] S.-J. Kim, J. W. Kim, S.-W. Han et al., "Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy," BMC Cancer, vol. 10, no. 1, pp. 1–11, 2010.
[10] P.-Y. Huang, K.-L. Tsai, C.-M. Liang et al., "Prognostic factors of patients with gastroenteropancreatic neuroendocrine neoplasms," The Kaohsiung Journal of Medical Sciences, vol. 34, no. 11, pp. 650–656, 2018.
[11] O. Basturk, L. Tang, R. H. Hruban et al., "Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases," The American Journal of Surgical Pathology, vol. 38, no. 4, pp. 437–447, 2014.
[12] G. Luo, A. Javed, J. R. Strosberg et al., "Modified staging classification for pancreatic neuroendocrine tumors on the basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society systems," Journal of Clinical Oncology, vol. 35, no. 3, pp. 274–280, 2017.
[13] Y. Gao, H. Gao, G. Wang et al., "A meta-analysis of prognostic factor of pancreatic neuroendocrine neoplasms," Scientific Reports, vol. 8, no. 1, pp. 1–8, 2018.
[14] Y. Shin, S. Y. Ha, J. Hyeon et al., "Gastroenteropancreatic neuroendocrine tumors with liver metastases in Korea: a clinicopathological analysis of 72 cases in a single institute," Cancer Research and Treatment, vol. 47, no. 4, pp. 738–746, 2015.
[15] K. J. Keck, A. Choi, J. E. Maxwell et al., "Increased grade in neuroendocrine tumor metastases negatively impacts survival," Annals of Surgical Oncology, vol. 24, no. 8, pp. 2206–2212, 2017.
[16] Y. Liu, S. Ye, Y. Zhu et al., "Impact of tumour size on metastasis and survival in patients with pancreatic neuroendocrine tumours (PNETs): a population based study," Journal of Cancer, vol. 10, no. 25, pp. 6349–6357, 2019.
[17] G. Klöppel, G. Rindi, A. Perren, P. Krommino, and D. S. Klimstra, "The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement," Virchows Archiv, vol. 456, no. 6, pp. 595–597, 2010.
[18] Y. Yamamoto, Y. Okamura, S. Uemura et al., "Vascularity and tumor size are significant predictors for recurrence after resection of a pancreatic neuroendocrine tumor," Annals of Surgical Oncology, vol. 24, no. 8, pp. 2363–2370, 2017.
[19] G. Yang, M. Ji, J. Chen et al., "Surgery management for sporadic small (≤2 cm), non-functioning pancreatic neuroendocrine tumors: a consensus statement by the Chinese Study Group for neuroendocrine tumors (CSNET)," International Journal of Oncology, vol. 50, no. 2, pp. 567–574, 2017.
[20] G. Spolverato, F. Bagante, D. Wagner et al., "Quality of life after treatment of neuroendocrine liver metastasis," Journal of Surgical Research, vol. 198, no. 1, pp. 155–164, 2015.
[21] M. Zheng, Y. Li, T. Li, L. Zhang, and L. Zhou, "Resection of the primary tumor improves survival in patients with gastroentero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis," Cancer Medicine, vol. 8, no. 11, pp. 5128–5136, 2019.
[22] R. Souche, C. Hobeika, E. Hain, and S. Gaoujoux, "Surgical management of neuroendocrine tumours of the pancreas," Journal of Clinical Medicine, vol. 9, no. 9, p. 2993, 2020.
[23] K. Shimata, Y. Sugawara, and T. Hibi, "Liver transplantation for unresectable pancreatic neuroendocrine tumors with liver metastases in an era of transplant oncology," Gland Surgery, vol. 7, no. 1, pp. 42–46, 2018.
[24] J. Kim, M. A. Zimmerman, and J. C. Hong, "Liver transplantation in the treatment of unresectable hepatic metastasis from neuroendocrine tumors," Journal of Gastrointestinal Oncology, vol. 11, no. 3, pp. 601–608, 2020.